Lesley Seymour

Queen's University — Canada

Medicine · Health Sciences

76h-index35.1kcitations375works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(165), Colorectal Cancer Treatments and Studies(58), Cancer Genomics and Diagnostics(54), Lung Cancer Research Studies(53), Lung Cancer Diagnosis and Treatment(48)

Publications373 total

Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [<sup>18</sup>F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response
2025Open Access
Abstract C072: Comparing and combining existing radiological criteria for hyperprogressive disease in patients receiving immune-oncology therapy: Building towards a sensitive and conservative method to assess the presence of hyperprogressive disease
Molecular Cancer Therapeutics·2025
Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials
Immunotherapy·2025
2457P CDK12 as a prostate cancer predisposition gene
Annals of Oncology·2025
IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.
Journal of Clinical Oncology·2025· 1 cited
Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).
Journal of Clinical Oncology·2025
Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).
Journal of Clinical Oncology·2025
Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)–directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2025· 2 cited
Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.
Journal of Clinical Oncology·2025
Abstract CT239: IND.241: A Canadian cancer trials group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer
Cancer Research·2025
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data
Immunotherapy·2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Journal of Clinical Oncology·2025· 7 cited
Supplementary Table 1 from Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Data from Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
2025Open Access
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
EClinicalMedicine·2025· 4 citedOpen Access
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
EClinicalMedicine·2025· 1 citedOpen Access
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research·2024· 5 cited
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable
UNC Libraries·2024Open Access
467 (PB455): IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER +/HER2- metastatic breast cancer
European Journal of Cancer·2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable
EClinicalMedicine·2024· 12 citedOpen Access
page 1 of 19Next →

Frequent Co-authors

Frances A. Shepherd(37), Keyue Ding(21), Ming‐Sound Tsao(15), Jean-Yves Douillard(10), Jean‐Pierre Pignon(9), Thierry Le Chevalier(8), Marlo Whitehead(8), Dongsheng Tu(7), Andrea Bezjak(6), Timothy Winton(6), Stephen L. Graziano(6), Robert A. Kratzke(6), Gwénaël Le Teuff(6), Jean‐Charles Soria(6), Rafael Rosell(5), Chang‐Qi Zhu(5), Robert B. Livingston(5), James R. Rigas(5), Charles Butts(5), Barbara Graham(5)